Dernières nouvelles pour Invivyd (NASDAQ:IVVD) Stock

INVIVYD INC

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

TELUS Health combines digital-first innovation with Workplace Options' Employee and Family Assistance Program to transform employee wellbeing solutions
GTCR to invest US$200 million as part of the acquisition, bringing strategic healthcare industry expertise to accelerate TELUS Health's global growth and innovation
VANCOUVER, BC and TORONTO, May 14, 2025 /PRNewswire/ - TELUS Corporation ("TELUS") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/T#TSX">T</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TU#NYSE">TU</a>) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately $500 million (US$350 million), net of assumed debt of approximately $100 million (US$70 million). Workplace Options, a leading global provider of integrated employee wellbeing solutions across 200 countries and territories, further solidifies TELUS Health as an unparalleled force in the global wellbeing solutions market. Today, TELUS Health is one of the largest companies providing digital-first health and wellbeing services and solutions globally to empower individuals to live their healthiest lives. TELUS Health is now positioned to support clients across all channels and global verticals covering more than 150 million lives and growing.

News

TSX:T

TELUS Announces Strategic Partnership With GTCR, Supporting TELUS Health's Recently Announced Acquisition Of Workplace Options

Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 28.57 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $513.00 thousand which missed the analyst consensus estimate of $654.00 thousand by 21.56 percent. This is a 36.98 percent decrease over sales of $814.00 thousand the same period last year.

Earnings

Earnings Misses

NEON

Neonode Q1 EPS $(0.10) Misses $(0.08) Estimate, Sales $513.00K Miss $654.00K Estimate

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
– Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial –
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple abstracts showcasing clinical data for Revuforj&#xAE; (revumenib) and Niktimvo&#x2122; (axatilimab-csfr) were accepted for presentation at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy.

SNDX

Syndax Pharma: Multiple Abstracts Showcasing Clinical Data For Revuforj Accepted For Presentation At EHA Annual Congress Meeting

Primech Holdings Limited ("Primech" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>), an established technology-driven facility services provider in the public and private sectors operating mainly in Singapore, today announced that it has received notice from the Nasdaq Stock Market ("Nasdaq") on May 13, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market.&nbsp;

PMEC

Primech Regains Compliance With Nasdaq's Minimum Bid Price Requirement

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) announced Tuesday morning that its CEO, Andrew Witty, <a href="https://www.benzinga.com/quote/UNH/news">will resign for personal reasons..</a>
Stephen Hemsley, who previously held the CEO title from 2006 to 2017, will succeed him. Hemsley will also remain chairman of UnitedHealth's board of directors, and Witty will become senior adviser to the CEO.
The company also revealed that it would suspend its 2025 outlook, citing that care activity continued to accelerate.
UnitedHealth noted broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
It said it "expects to return to growth in 2026," according to the announcement.
The insurance giant reported adjusted EPS of $7.20 in April, up from $6.91 a year ago, missing the consensus of $7.29. Revenues increased 6.8% year over year to $109.6 billion, missing the consensus of $111.60 billion.
UNH shares gained 2.7% to trade at $319.78 on Wednesday.
These analysts made changes to their price targets on UNH following the announcement.
<ul class="wp-block-list">
<li>Keybanc analyst Matthew Gillmor maintained UnitedHealth Group with an Overweight rating and lowered the price target from $575 to $450.</li>
<li>Baird analyst Michael Ha maintained UnitedHealth Group with an Outperform rating and lowered the price target from $510 to $356.</li>
</ul>
Considering buying UNH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-1024x600.png" alt="" class="wp-image-915083" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14093304/image-164.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45402795/top-3-materials-stocks-that-could-blast-off-this-month">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Price Target

Markets

Analyst Ratings

Trading Ideas

These Analysts Slash Their Forecasts On UnitedHealth

Sumitomo Chemical (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOMMY#OTC">SOMMY</a>) reported quarterly earnings of $0.20 per share. This is a 104.81 percent increase over losses of $(4.16) per share from the same period last year. The company reported $4.60 billion in sales this quarter. This is a 6.65 percent increase over sales of $4.31 billion the same period last year.

SOMMY

Sumitomo Chemical Q4 EPS $0.20 Up From $(4.16) YoY, Sales $4.60B Up From $4.31B YoY

Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.

Biotech

General

KPTI

Karyopharm Announces Poster Presentation On Selinexor In Myelofibrosis At The 2025 EHA Annual Meeting

Events

AUTL

Autolus Therapeutics Presents Clinical Data Updates At 2025 European Hematology Association Congress

Scotiabank analyst Eric Winmill maintains Foran Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FOM#TSX">FOM</a>) with a Sector Outperform and lowers the price target from C$4.25 to C$4.

TSX:FOM

Scotiabank Maintains Sector Outperform on Foran Mining, Lowers Price Target to C$4

Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ET
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.schrodinger.com&amp;esheet=54254308&amp;newsitemid=20250514784901&amp;lan=en-US&amp;anchor=Schr%26ouml%3Bdinger&amp;index=1&amp;md5=17917a02592055143992a5e22a478133">Schrödinger</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland.
The Phase 1 study is designed to evaluate the safety, tolerability and anti-tumor activity of SGR-1505 in patients with relapsed/refractory B-cell malignancies. The poster presentations will include initial safety, pharmacokinetic and pharmacodynamic data, as well as preliminary efficacy data across a range of dosing levels, schedules and B cell malignancies. The data support the continued development of SGR-1505 in this patient population.

SDGR

Schrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
– Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial –

Syndax Presents Data Showcasing Revuforj And Niktimvo At EHA 2025

NRIX

Nurix Therapeutics Prersents Data From Ongoing Phase 1a/b Clinical Trial Of Bexobrutideg In Patients With r/r CLL And Waldenström Macroglobulinemia At EHA Congress 2025 And 18-ICML

<ul>
<li>Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteers</li>
<li>Management will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST &nbsp;</li>
</ul>
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.

IRON

Disc Medicine Announces Multiple Presentations Across Portfolio At The EHA 2025 Congress

B of A Securities analyst Kevin Fischbeck downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Buy to Neutral and lowers the price target from $560 to $350.

Downgrades

B of A Securities Downgrades UnitedHealth Group to Neutral, Lowers Price Target to $350

-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months --
-- No delayed neurotoxicities including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitis have been observed to date with anito-cel --
-- iMMagine-1 data to be presented during an oral presentation at EHA2025 on Saturday, June 14, 2025 --
-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 --
Arcellx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan on June 14, 2025. Anito-cel is partnered with Kite, a Gilead Company.
The Phase 2 iMMagine-1 data are from a May 1, 2025 data cutoff date, including all 117 patients with a median follow-up of 12.6 months and a minimum follow-up of four months after treatment with anito-cel. All patients received a single infusion of anito-cel (target dose of 115×106 CAR+ viable T cells). 101 of 117 patients (86%) were triple refractory, and 48 of 117 patients (41%) were penta refractory. Patients received a median of three prior lines of therapy, with 60 of 117 patients (51%) having received three prior lines.
Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (&gt;VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at the time of this data cut, 93.3% (70/75) achieved MRD negativity at a minimum of 10-5 sensitivity. Six-month progression-free survival (PFS) and overall survival (OS) rates were 91.9% and 96.6%, respectively, and 12-month PFS and OS rates were 78.8% and 95.2%, respectively. Median PFS and median OS have not been reached.
No delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, and no immune-mediated enterocolitishave been observed to date with anito-cel. No additional treatment- or therapy-related deaths or Grade ≥3 cytokine release syndrome (CRS) or ICANS events have occurred since the previous data presentation in December 2024.

ACLX

Arcellx Announces New Data For Its iMMagine-1 Study In Patients With Relapsed And/Or Refractory Multiple Myeloma;  Results From All 117 Patients Dosed In The Pivotal Phase 2 iMMagine-1 Study Of Anito-Cel Demonstrated 97% ORR And 68% CR/sCR At A Median Follow-Up Of 12.6 Months

Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent.

KAPA

Kairos Pharma Q1 EPS $(0.08) Misses $(0.05) Estimate

Scotiabank analyst Orest Wowkodaw maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Sector Perform and raises the price target from C$22 to C$22.5.

TSX:FM

Scotiabank Maintains Sector Perform on First Quantum Minerals, Raises Price Target to C$22.5

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14064639/Fuiou-0514-900x600-1.png" alt="" class="wp-image-12911" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14064639/Fuiou-0514-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14064639/Fuiou-0514-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14064639/Fuiou-0514-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The payment services provider looks well-positioned to benefit from China's consumption-boosting policies as it seeks to list
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Hong Kong IPO candidate Fuiou could get a lift from China's efforts to boost domestic consumption to reduce the country's heavy reliance on overseas demand</li>
<li>The payment services provider's revenue grew at an average rate of nearly 20% over the last two years, and it is also profitable</li>
</ul>
Boosting domestic consumption has become a critical focus for Beijing lately as Donald Trump's tariff bombs make export-reliant economies, like China's, more vulnerable than ever to big swings in external demand. That could translate to big business for Chinese companies tied to the domestic retail economy, at least in theory.
One potential beneficiary of such a boom, if it comes, could be&nbsp;Shanghai Fuiou Payment Service Corp. Ltd., which operates digital payment services. That makes the company well-positioned to capitalize on China's efforts to entice consumers into opening their wallets as Fuiou seeks to attract investors to its plan to list in Hong Kong.
Fuiou made a new&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107352/documents/sehk25050901426.pdf">public filing</a>, its third, for the IPO last Friday, painting itself as a pioneer in integrated digital payment services with "recognized brand dominance and a prominent market position." Citing third-party research, the company, founded in 2011, says it was among the first in China to offer multichannel digital payment software and additional services for e-commerce enterprises.
The Chinese government has rolled out a series of measures since last year to drive the country's economic growth through domestic consumption, as its traditional reliance on exports has left it exposed to growing protectionism across the globe. While China's exports continue to grow despite the pressures, foreign direct investment – another important economic engine that's also dependent on external factors – has already begun to shrink.
Government programs to boost consumer spending range from rebates for trade-ins of old home appliances and smartphones for new ones, to a grand initiative dubbed a "Special Action Plan to Boost Consumption." Against this backdrop, Citibank analysts this week upgraded China's overall consumer sector to "overweight," while also saying technology is one of the sectors that can benefit from Beijing's new policy focus.
As a provider of technology-based services that are directly tied to consumption, Fuiou appears to be in a sweet spot in China's current dull economy.
The company's recent financial performance looks decent enough, especially considering its position in China's fiercely competitive payment services sector. In the last two years, the company's revenue grew at an average annual rate of nearly 20% to 1.6 billion yuan ($221 million) in 2024. And it's stably profitable, although not hugely. It made a net profit of 84 million yuan last year, giving it a net profit margin of about 5%.
Fuiou gets more than 80% of its revenue from "acquiring" services, which help merchants, both online and traditional brick-and-mortar shop operators, collect funds from their customers. The company has processed more than 54 billion transactions worth 15.1 trillion yuan in total payment value (TPV) since its inception, the most among independent providers of integrated digital payment services in China, Fuiou said in its IPO document, citing third-party data.
<h4 class="wp-block-heading">High-margin services</h4>
Apart from its main transaction-processing services, "digital commerce-enabling solutions" are an emerging income source for the company. Such solutions include software as a service (SaaS), digital marketing services, account operations and invoicing for merchants. This business accounted for 7% of Fuiou's revenue last year, up from 5.3% in 2023. Margins on these services are also relatively high, so Fuiou is looking to expand them to boost its profitability.
The company has also been successful in controlling costs. Its operating expenses amounted to 22% of its revenue in 2022, and it managed to reduce that ratio to 19% last year.
While the company's story sounds good on the whole, there are also some red flags. While the recent 20% average annual revenue growth looks solid, a closer look shows that Fuiou's growth slowed sharply last year. Its revenue increased by nearly a third in 2023, but then rose just about 8.5% last year.
The jump in 2023 probably owed mostly to the lifting of China's strict Covid-19 restrictions at the end of the previous year, which resulted in a wave of "revenge spending" as shops reopened and consumption returned to more normal levels. So, that kind of growth isn't likely to be repeated any time soon. Last year's more tepid growth is more likely to represent the norm going forward, as China's economy slows after the brief post-pandemic rally.
China intensified its efforts to stimulate domestic consumption only late last year, so it may take some time before notable results start to become evident, as the domestic economy remains on a weak footing amid the ongoing real estate slump, on top of global trade tensions. Retail sales increased a modest 4% year-on-year in the first two months of this year, slightly faster than 3.5% in 2024. In releasing the March figure, the National Bureau of Statistics said that "the foundation for sustained economic recovery and growth" is not solid enough.
Retail sales growth accelerated to 6% in March, but it remains to be seen whether that pace is sustainable. Fundamentally, low levels of household income and uneven wealth distribution in general are restraining consumption in China, Rhodium Group said in a report last July. That means that without significant changes in fiscal policy, household consumption growth in the country is likely to stay at 3%-4% in real terms in the next five to 10 years, the researcher said.
Fuiou also operates in a highly competitive industry that is dominated by giants like Alipay and WeChat, which are both part of much larger companies. Fuiou had a market share of just 0.8% in terms of total payment volume last year, so it may inevitably need to sacrifice its margins to gain share.
Shares of another payment services provider,&nbsp;Lianlian DigiTech&nbsp;(2598.HK), have fallen about 35% since the company's Hong Kong IPO last year. While it remains well in the red, unlike Fuiou, Lianlian trades at a relatively respectable price-to-sales (P/S) ratio of 4.5 – a multiple that would value Fuiou at 7.2 billion yuan, or roughly $1 billion, based on its 2024 revenue.
Given that Fuiou is profitable, investors may be more interested in its potential, seeing it as a fresh opportunity to buy into China's consumption growth story. But it may also face a fair amount of skepticism and caution in the absence of evidence that China's consumption-boosting measures are having the desired effect.

Asia

IPOs

Opinion

This Hong Kong IPO Candidate May Benefit From Policy Tailwinds

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are soaring again Wednesday after rising 16% on Tuesday. Here&#8217;s a look at <a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">what&#8217;s going on</a>.
What To Know: Super Micro shares surged alongside the broader market to start the week after the U.S. and China agreed to a temporary<a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation" target="_blank" rel="noreferrer noopener">&nbsp;trade deal</a>&nbsp;over the weekend. The world&#8217;s two biggest economies struck a deal in which the U.S. will lower tariffs on Chinese goods from 145% to 30%, and China will cut tariffs on U.S. goods from 125% to 10%.
Super Micro shares continued to rise on Tuesday amid positive analyst coverage. The company also announced the shipping&nbsp;launch of new micro cloud servers powered by AMD EPYC 4005 Series processors, optimized to balance performance density, scalability and affordability.
&#8220;These servers offer up to 2080 cores on a standard 42U rack, greatly reducing data center rack space and overall TCO for enterprise and small and medium businesses,&#8221; said Mory Lin, vice president, IoT/Embedded &amp; Edge Computing at Super Micro.
Raymond James analyst Simon Leopold initiated coverage on Super Micro with an <a href="https://www.benzinga.com/analyst-stock-ratings">Outperform rating</a> and set a price target of&nbsp;$41, which helped fuel continued momentum in the name. 
The analyst firm said the company is in a <a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">&#8220;sweet spot"</a> between traditional IT vendors and contract manufacturers. Analysts at Raymond James highlighted the company&#8217;s strong growth, which has been overshadowed by internal financing controls, which came under scrutiny after Super Micro&#8217;s independent auditor&nbsp;resigned last October over&nbsp;governance and transparency concerns, which led the company to delay the filing of its quarterly and full-year results.
Super Micro last reported quarterly results on May 6. The company reported adjusted earnings of 31 cents per share, missing analyst estimates of 50 cents per share, and revenue of $4.6 billion, below forecasts of $5.42 billion. 
Check This Out: <a href="https://www.benzinga.com/news/large-cap/25/05/45405067/saudi-arabia-bets-big-on-ai-teams-up-with-aws-and-nvidia">Saudi Arabia Bets Big On AI, Teams Up With AWS And NVIDIA</a>
The company preannounced results in late April, citing delayed customer platform decisions that moved sales into the fourth quarter.
&#8220;We do expect many of those commitments to land in the June and September quarters, reinforcing my confidence in our ability to meet our long-term targets, however, economic uncertainty and tariff impacts may have a short-term impact. We believe that we are well-positioned in the long term to capitalize on the growing market opportunity,&#8221; CEO Charles Liang <a href="https://www.benzinga.com/news/earnings/25/05/45236823/super-micro-computer-stock-slips-after-q3-results-uncertainty-and-tariffs-may-have-a-short-term-impact-ceo-says">said</a> in the earnings release. 
Several tech stocks are getting a boost after signing deals in Saudi Arabia this week. Saudi Arabian data center company DataVolt <a href="https://data-volt.com/media/breaking-news/datavolt-announces-landmark-deal-with-supermicro-to-accelerate-adoption-of-rack-scale-total-liquid-cooling-it-solutions-for-future-ready-ai-data-centers/">announced</a> a new deal with Super Micro after the market close on Tuesday, which appears to be helping drive momentum on Wednesday.
The companies signed a multi-year partnership agreement to fast-track the delivery of ultra-dense GPU platforms and rack systems for DataVolt's hyperscale AI locations.
&#8220;We are excited to partner with DataVolt and continue expanding our manufacturing efforts in the United States. By working together, we will bring cutting-edge AI and compute infrastructure, enabling the Kingdom's vision of becoming a global hub for technology and innovation,&#8221; Liang said in a statement.
SMCI Price Action: <a href="http://benzinga.com/quote/smci">Super Micro shares</a> were up 17.0% at $45.54 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

SMCI

Super Micro Computer Stock Is Surging Again: What's Going On?

B of A Securities analyst Fiona Liang initiates coverage on EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) with a Buy rating and announces Price Target of $26.

Initiation

B of A Securities Initiates Coverage On EHang Holdings with Buy Rating, Announces Price Target of $26

Press Releases

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Management

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Comments

Invivyd

Actualités

Dernières nouvelles pour Invivyd (NASDAQ:IVVD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL